Haemonetics Co. (HAE) Position Boosted by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC lifted its holdings in Haemonetics Co. (NYSE:HAE) by 229.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,554 shares of the medical instruments supplier’s stock after purchasing an additional 73,483 shares during the period. O Shaughnessy Asset Management LLC owned about 0.20% of Haemonetics worth $12,059,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in HAE. CIBC Asset Management Inc purchased a new position in shares of Haemonetics in the 3rd quarter valued at about $219,000. Wagner Bowman Management Corp purchased a new position in shares of Haemonetics in the 2nd quarter valued at about $224,000. Arjuna Capital purchased a new position in shares of Haemonetics in the 2nd quarter valued at about $224,000. Granahan Investment Management Inc. MA purchased a new position in shares of Haemonetics in the 2nd quarter valued at about $229,000. Finally, Welch & Forbes LLC purchased a new position in shares of Haemonetics in the 3rd quarter valued at about $229,000. Hedge funds and other institutional investors own 96.44% of the company’s stock.

HAE stock opened at $111.61 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.94 and a current ratio of 2.92. Haemonetics Co. has a 12-month low of $53.74 and a 12-month high of $117.56. The stock has a market capitalization of $5.95 billion, a P/E ratio of 59.68, a PEG ratio of 3.67 and a beta of 1.09.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $0.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.54 by $0.02. Haemonetics had a return on equity of 16.04% and a net margin of 2.26%. The company had revenue of $241.58 million for the quarter, compared to analysts’ expectations of $233.44 million. During the same period in the previous year, the firm posted $0.48 EPS. Haemonetics’s revenue was up 7.2% compared to the same quarter last year. As a group, analysts expect that Haemonetics Co. will post 2.33 earnings per share for the current year.

In related news, SVP Jacqueline Scanlan sold 4,890 shares of Haemonetics stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $112.19, for a total value of $548,609.10. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Pedro P. Granadillo sold 30,824 shares of Haemonetics stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $111.83, for a total value of $3,447,047.92. The disclosure for this sale can be found here. Over the last quarter, insiders sold 62,653 shares of company stock worth $6,973,391. 1.04% of the stock is currently owned by insiders.

Several equities analysts recently weighed in on the company. Zacks Investment Research upgraded Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 price target for the company in a research note on Friday, October 12th. Barrington Research restated a “buy” rating and issued a $127.00 price target on shares of Haemonetics in a research note on Friday, October 5th. TheStreet cut Haemonetics from a “b” rating to a “c+” rating in a report on Monday, August 20th. Morgan Stanley lifted their price objective on Haemonetics from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, August 8th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price objective on shares of Haemonetics in a report on Tuesday, August 7th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $113.20.

ILLEGAL ACTIVITY NOTICE: “Haemonetics Co. (HAE) Position Boosted by O Shaughnessy Asset Management LLC” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/11/10/haemonetics-co-hae-position-boosted-by-o-shaughnessy-asset-management-llc.html.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Read More: Earnings Per Share

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply